Loading clinical trials...

Improving Social Functioning in People With Substance Use and Mental Health Disorders Using VR | Clinical Trials | Clareo Health

RECRUITINGNA

Improving Social Functioning in People With Substance Use and Mental Health Disorders Using VR

Improving Social Functioning in People With Substance Use and Mental Health Disorders Using Virtual Reality (ROPVR): Study Protocol for a Multi-centre, Pragmatic Randomized Controlled Trial

NCT06677515•Sykehuset Innlandet HF

View on ClinicalTrials.gov

Summary

ROPVR, a multi-centre, pragmatic randomized controlled trial (RCT) aims to evaluate a VR-technology which has been developed within an exploratory study and a development study, which facilitates social functioning among persons with a substance use and mental health disorder. Investigators will test a VR-program versus treatment as usual among patients enrolled into a long-term addiction-treatment facility. The RCT aims to evaluate the effectiveness of VR training compared to treatment as usual in improving resilience, quality of life, practical and social functioning and social participation (from baseline to 6 months), and to evaluate the cost-effectiveness of VR training versus treatment as usual.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•adults aged 18 years or older receiving in-patient SUD treatment in specialized addiction treatment units in South-East Norway. This may include persons serving prison sentences during in-patient treatment according to the Execution of Sentences Act in Norway
•having the capability to read, understand and sign the Norwegian informed consent form
•willing and able to attend VR training two times a week for 5 weeks

Exclusion Criteria

•significant visual, auditory, or balance impairment or other diseases affecting safety during VR sessions (e.g., epilepsy)
•current clinically significant severe mental health disorder (e.g., acute episode of psychosis or current active suicidal plans). Persons with psychotic disorders or other severe mental illness are not excluded if their condition is stable.
•severe travel sickness as a proxy for simulation sickness

Locations (2)

Innlandet Hospital Trust

Brumunddal, Norway

Sykehuset Innlandet HF

Hamar, Norway

Key Dates

Start Date

May 8, 2025

Primary Completion Date

June 1, 2026

Completion Date

December 1, 2026

Last Updated

January 23, 2026

Enrollment

102

ESTIMATED participants

Conditions

Substance Use DisordersMental Disorder

Interventions

VR training

OTHER

Contacts

Marja Leonhardt, PhD

CONTACT

+4747150465 marja.leonhardt@sykehuset-innlandet.no

Lars Lien, MD, PhD

CONTACT

+4797040683 lars.lien@sykehuset-innlandet.no

Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders

NCT01778504

Neuropsychiatric DisorderNeurological Disorder+2 more

View study

RECRUITING

Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal

NCT06690151

Heart Disease CongenitalNeurodevelopmental Disorder

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 23, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Improving Social Functioning in People With Substance Use and Mental Health Disorders Using VR

Inclusion Criteria

Exclusion Criteria

Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders

Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal

Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)

Psychiatric Multi-omics and Neuroimaging Project

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use